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Objective: We compared the physiologic effect of selective atropine administration for bradycardia with routine prophy-
lactic administration, before balloon inflation, during carotid angioplasty and stenting (CAS). We also compared the
incidence of procedural bradycardia and hypotension for CAS in patients with primary stenosis vs those with prior
ipsilateral carotid endarterectomy (CEA).
Methods: A total of 86 patients were treated with CAS at 3 institutions. Complete periprocedural information was
available for 75 of these patients. The median degree of stenosis was 90% (range, 60%-99%). Indications for CAS were
severe comorbidities (n  49), prior CEA (n  21), and prior neck radiation (n  5). Twenty patients with primary
lesions were treated selectively with atropine only if symptomatic bradycardia occurred (nonprophylactic group).
Thirty-four patients with primary lesions received routine prophylactic atropine administration before balloon inflation
or stent deployment (prophylactic group). The 21 patients with prior CEA received selective atropine treatment only if
symptomatic bradycardia occurred (prior CEA group) and were analyzed separately. Mean age and cardiac comorbidities
did not vary significantly either between the prophylactic and nonprophylactic atropine groups or between the primary
and prior CEA patient groups. Outcome measures included bradycardia (decrease in heart rate >50% or absolute heart
rate<40 bpm), hypotension (systolic blood pressure<90mmHg ormean blood pressure<50mmHg), requirement for
vasopressors, and cardiac morbidity (myocardial infarction or congestive heart failure).
Results: The overall incidence of hypotension and bradycardia in patients treated with CAS was 25 (33%) of 75. A
decreased incidence of intraoperative bradycardia (9% vs 50%; P< .001) and perioperative cardiac morbidity (0% vs 15%;
P< .05 ) was observed in patients with primary stenosis who received prophylactic atropine as compared with patients
who did not receive prophylactic atropine. CAS after prior CEA was associated with a significantly lower incidence of
perioperative bradycardia (10% vs 33%; P< .05), hypotension (5% vs 32%; P< .05), and vasopressor requirement (5% vs
30%; P < .05), with a trend toward a lower incidence of cardiac morbidity (0% vs 6%; not significant) as compared with
patients treated with CAS for primary carotid lesions. There were no significant predictive demographic factors for
bradycardia and hypotension after CAS.
Conclusions: The administration of prophylactic atropine before balloon inflation during CAS decreases the incidence of
intraoperative bradycardia and cardiac morbidity in primary CAS patients. Periprocedural bradycardia, hypotension, and
the need for vasopressors occur more frequently with primary CAS than with redo CAS procedures. On the basis of our
data, we recommend that prophylactic atropine administration be considered in patients with primary carotid lesions
undergoing CAS. (J Vasc Surg 2005;41:956-61.)Carotid angioplasty and stenting (CAS) has been per-
formed with increasing frequency for the treatment of
carotid occlusive disease. The safety of CAS has been sup-
ported by the recent SAPPHIRE trial,1 which revealed a
lower incidence of stroke, death, and myocardial infarction
(MI) with CAS compared with carotid endarterectomy
(CEA) in high-risk patients.
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956Bradycardia and hypotension have been observed after
CAS with a reported incidence of 7% to 76%.2-8 The causative
factor is believed to be stimulation of the carotid sinus barore-
ceptors by the angioplasty balloon and intravascular stent.
Stimulation of baroreceptors located in the carotid bifurcation
causes an increase in afferent signals via the carotid sinus and
glossopharyngeal nerves to the caudal medulla. The medulla
then regulates a temporary increase in parasympathetic im-
pulses and a decrease in sympathetic vascular tone, with result-
ant bradycardia and hypotension.9 These hemodynamic
changes induced by CAS may place the patient at risk for
perioperative cardiac events. Atropine can block the parasym-
pathetic impulses and has been used in an attempt to prevent
or treat the resultant bradycardia and hypotension.
This study evaluated the physiologic effect of routine
prophylactic atropine administration before balloon inflation
or stent deployment during CAS. A comparison of the inci-
JOURNAL OF VASCULAR SURGERY
Volume 41, Number 6 Cayne et al 957dence of procedural bradycardia and hypotension for CAS in
patients with primary lesions vs those with prior CEAwas also
performed.
METHODS
We retrospectively reviewed prospectively collected
data from a registry of 86 consecutive patients who under-
went elective CAS at 3 institutions between September
2002 and April 2004. Complete data were available for 75
of these patients. All cases were performed under local
anesthesia by vascular surgeons either in the angiography
suite or in the operating room. Indications for intervention
were greater than 50% stenosis in symptomatic patients
(32%) and greater than 80% stenosis in asymptomatic pa-
tients. The degree of stenosis was determined by angiogra-
phy by using North American Symptomatic Carotid End-
arterectomy Trial measurement criteria.10 The median
degree of stenosis for our patient population was 90%
(range, 60%-99%). Indications for CAS over CEA were
severe comorbidities (n  49), prior ipsilateral CEA (n 
21), and prior neck radiation (n  5).
All patients were monitored and received routine fluid
administration throughout the procedure. Bradycardia and
hypotension during the procedure were initially treated at
the discretion of the surgeon or anesthesiologist with atro-
pine (0.5- to 1-mg doses) and additional fluid administra-
tion immediately after the event. After observing significant
bradycardia and hypotension during balloon inflation in 20
initial patients with primary lesions, we began using atro-
pine prophylactically, just before balloon inflation, during
the procedure.
Twenty initial patients with primary lesions were treated
selectively with atropine only after symptomatic bradycardia
developed (nonprophylactic group). A later group of 34 pa-
tients with primary lesions received routine prophylactic atro-
pine administration (0.5-1 mg) before balloon inflation or
stent deployment (prophylactic group). Twenty-one patients
with prior ipsilateral CEA received selective atropine treat-
ment only if symptomatic bradycardia developed (prior CEA
group), again at the discretion of the surgeon or anesthesiol-
ogist. This group of patients was noted by the authors to have
a substantially lower incidence of CAS-induced bradycardia
and hypotension and therefore were analyzed separately from
those with primary lesions.
Vasopressors or inotropes were used as necessary if
additional atropine and fluid administration were not suffi-
cient. Dopamine was usually used in increasing doses as a
first-line drug, and phenylephrine or norepinephrine was
added as needed.
All patients were given oral aspirin (325 mg daily for 2
days) and clopidogrel (300mg the day prior or 75mg twice
daily for 2 days) or ticlopidine (250 mg twice daily for 2
days) before surgery. Aspirin was continued indefinitely,
and clopidogrel or ticlopidine was continued for at least 4
to 6 weeks after surgery.
Cerebral protection devices (Percusurge [Medtronic,
Santa Rosa, Calif], Filterwire [Boston Scientific, Natick,
Mass], or Accunet [Guidant, Santa Clara, Calif]) were usedin all patients with primary lesions and in 18 of 21 patients
with prior ipsilateral CEA. All stents used in this study were
self-expanding stents: Wall (Boston Scientific), Precise
(Cordis, Miami, Fla), or Acculink (Guidant).
For the carotid stent procedure, cases were performed
under local anesthesia. A 5F sheathwas placed in the common
femoral artery by the Seldinger technique. An angiogram was
performed of the aortic arch and great vessels via a 5F pigtail
catheter. Heparin was given intravenously (100 U/kg) to
achieve an activated clotting timemore than250 seconds.The
affected carotid artery was selectively catheterizedwith a Vitek
(Cook Inc, Bloomington, Ind) or angled glide catheter (Bos-
ton Scientific). A selective carotid cervical and cerebral angio-
gram was performed in at least two views. After confirmation
of the lesion, the catheter was advanced over a 0.035-inch
glide wire (Boston Scientific) into the external carotid artery,
and a stiff 0.035-inch Glidewire or Amlpatz (Boston Scien-
tific) wire was used to exchange the 5F sheath to a 90-cm 6F
or 7F Shuttle (Cook Inc). The sheath was advanced into the
common carotid artery proximal to the carotid bifurcation.
The lesion was crossed with the protection device, and the
filter was deployed or the protection balloon was inflated in a
straight portion of internal carotid artery at least 2 cm distal to
the lesion. If necessary, predilationwas performedwith a 3- or
4-mm balloon. A self-expanding stent was delivered and de-
ployed across the lesion. Postdilation was performed with a 4-
to 6-mm balloon. Care was taken not to overdilate to a
diameter larger than the distal internal carotid artery. When a
filter was used, a completion angiogram was performed, and
the filter was recaptured.When a protection balloonwas used,
the columnof stagnant blood in the internal carotid arterywas
aspirated, and the protection balloon was deflated before the
completion angiogram.
Blood pressure and heart rate (HR) were monitored
continuously throughout the procedure. The patients were
placed in a monitored setting (intensive care unit or step-
down unit) with continuous monitoring for at least 24 hours.
Any intraoperative or postoperative (up to 24 hours) brady-
cardia (HR 40 bpm or decrease 50%) or hypotension
(systolic bloodpressure90mmHgormean arterial pressure
50 mm Hg) was recorded. Instances of tachycardia (HR
100 bpm or increase 50%) were also recorded. In addi-
tion, evidence of cardiacmorbidity, defined asMI on the basis
of cardiac enzymes or electrocardiogram or clinical evidence
of congestive heart failure (CHF), was noted. Cardiac en-
zymes (troponin) and electrocardiogram were checked at a
minimum immediately after the procedure and the morning
after the procedure. Outcomes included the incidence of
bradycardia, hypotension, cardiac morbidity, and the use of
vasopressors to maintain adequate blood pressure. Intraoper-
ative, postoperative (24 hours after the conclusion of the
operation), and perioperative (intraoperative plus postopera-
tive) time periods were evaluated.
Data were analyzed by using standard statistical meth-
ods. Categorical variables were compared by using the
Fisher exact test, and continuous variables were evaluated
by using analysis of variance and the Student t test. All
continuous values are represented as mean  SD; correla-
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tions were performed with SPSS (version 10.0) for Win-
dows (SPSS Inc, Chicago, Ill).
RESULTS
Mean ages and comorbidities did not differ significantly
Table I. Demographics: comparison of all patients with p
prophylactic group
Variable All primary (n  54)
Age, y (mean  SD) 74.1  11
Male 74%
Female 26%
Hypertension 80%
Hypercholesterolemia 41%
CAD* 57%
Prior MI 32%
CHF 24%
Diabetes 32%
CRI† 11%
Smoking 59%
Prior stroke 19%
COPD‡ 15%
Neck radiation 9%
Symptomatic§ 26%
-Blockers 56%
% Stenosis (mean  SD) 86.1%  10%
MI, Myocardial infarction; CHF, congestive heart failure.
*CAD (coronary artery disease): history of myocardial infarction, angina, o
†CRI (chronic renal insufficiency): preoperative creatinine 1.5 mg/dL.
‡COPD (chronic obstructive pulmonary disease): forced expiratory volume
75.
§History of transient ischemic event or stroke.
Table II. Demographics: comparison of patients with prim
(CEA)
Variable All (n  75)
Age, y (mean  SD) 73.4  10
Male 65%
Female 35%
Hypertension 81%
Hypercholesterolemia 40%
CAD* 57%
Prior MI 28%
CHF 19%
Diabetes 26%
CRI† 13%
Smoker 61%
Prior stroke 22%
COPD‡ 14%
Neck radiation 8%
Symptomatic§ 32%
-Blockers 56%
% stenosis (mean  SD) 85.6%  11%
MI, Myocardial infarction; CHF, congestive heart failure.
*CAD (coronary artery disease): history of myocardial infarction, angina, o
†CRI (chronic renal insufficiency): preoperative creatinine 1.5.
‡COPD (chronic obstructive pulmonary disease): forced expiratory volume
75.
§History of transient ischemic event or stroke.either between the prophylactic and nonprophylactic atropineadministration groups (Table I) or between the primary lesion
and prior CEA groups (Table II). The mean age overall was
73  10 years (range, 45-93 years). Overall, there were
significantly (P  .05) more men (65%) than women (35%).
The smaller subgroup of patients with prior CEA had signifi-
cantly more women (62%) compared with those who had
y lesions, the nonprophylactic group, and the
Nonprophylactic (n  20) Prophylactic (n  34)
75.7  11 73.2  10
65% 79%
35% 21%
90% 74%
45% 37%
70% 50%
35% 29%
25% 24%
40% 27%
5% 15%
55% 62%
25% 15%
25% 9%
10% 9%
35% 21%
55% 56%
85.4%  12% 86.5%  9%
rocardiographic evidence of myocardial ischemia.
econd 1 L or forced expiratory volume in 1 second/forced vital capacity
lesions and patients with prior carotid endarterectomy
Primary (n  54) Prior CEA (n  21)
74.1  11 71.3  8
74% 38%
26% 62%
80% 83%
41% 39%
57% 56%
32% 17%
24% 6%
32% 11%
11% 17%
59% 67%
19% 33%
15% 11%
9% 6%
26% 50%
56% 59%
86.1%  10% 84.5%  13%
rocardiographic evidence of myocardial ischemia.
econd 1 L or forced expiratory volume in 1 second/forced vital capacityrimar
r elect
in 1 sary
r elect
in 1 sprimary lesions (P .01).
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was 25 (33%) of 75. Twenty-eight percent of patients had
periprocedural bradycardia, and 24% had periprocedural hy-
potension. Intraoperative hypotension was associated with an
increased incidence of postoperative hypotension (P .001).
The overall incidence of periprocedural tachycardia was 10%,
and this was similar in the prophylactic (9%) and nonprophy-
lactic (10%) groups. Thirty-five percent of the nonprophylac-
tic group required atropine for bradycardia during CAS.
Adecreased incidence of intraoperative bradycardia (9% vs
50%; P  .001) and perioperative cardiac morbidity (0% vs
15%; P  .05 ) was observed in the prophylactic group as
compared with the nonprophylactic atropine group (Tables
III and IV). The mean starting HR for all patients with
primary lesions was 71 bpm. There was no significant differ-
ence in mean starting HRs in the nonprophylactic group (71
 19 bpm) and the prophylactic group (71 10 bpm). The
use of perioperative -blockade was similar in the nonprophy-
lactic group (53%) and the prophylactic group (56%; not
significant). Themeanminimum intraoperativeHRwas lower
for the nonprophylactic group than for the prophylactic group
(52  14 bpm vs 64  17 bpm; P  .05). A decreased
incidence of perioperative bradycardia (21% vs 55%; P .05)
was observed in the prophylactic group as compared with the
nonprophylactic group (Table IV). In addition, there was a
trend toward a lower incidence of perioperative hypotension
(24% vs 45%) and vasopressor requirement to maintain ade-
Table III. Comparison of intraoperative hemodynamic ch
groups
Variable Bradycardia
Nonprophylactic atropine 10/20 (50%)
Prophylactic atropine 3/34 (9%)
P value .001
NS, Not significant.
Table IV. Comparison of perioperative hemodynamic cha
groups
Variable Bradycardia H
Nonprophylactic atropine 11/20 (55%) 9
Prophylactic atropine 7/34 (21%) 8
P value .05
NS, Not significant.
Table V. Comparison of intraoperative hemodynamic cha
prior ipsilateral CEA
Variable Bradycardia
Primary 13/54 (24%)
Prior CEA 1/21 (5%)
P value NS
CEA, Carotid endarterectomy.quate HR or blood pressure (27% vs 35%) in the prophylacticgroup comparedwith the non-prophylactic group (not signif-
icant; Table IV).
Perioperative cardiac eventswere significantly lower in the
prophylactic group comparedwith thenonprophylactic group
(0% vs 15%; P .05). Two of the three patients with cardiac
events in the nonprophylactic group experienced anMI diag-
nosed by electrocardiogram and cardiac enzymes. The re-
maining patient had an episode of CHF that required a
prolonged stay in the intensive care unit. All three patients
experienced intraoperative bradycardia, and two of the three
experienced hypotension that necessitated vasopressor sup-
port. The one patient with an episode of CHF was receiving
preoperative -blocker medication, whereas the two MI pa-
tients were not.
CAS after prior CEAwas associated a decreased incidence
of intraoperative hypotension (5% vs 26%; P  .05) and
vasopressor requirement (0% vs 19%; P  .05) as compared
with patients treated by CAS for primary carotid lesions (Table
V). Patients with prior CEA also had a significantly reduced
incidence of perioperative bradycardia (10% vs 33%; P .05),
hypotension (5% vs 32%; P  .05), and vasopressor require-
ment (5% vs 30%; P  .05), with a trend toward overall
reduced cardiac morbidity (0% vs 6%; not significant; Table
VI).
Six patients with primary lesions (three prophylactic
and three nonprophylactic) experienced perioperative tran-
sient neurologic deficits. Five occurred during balloon in-
s between the nonprophylactic and prophylactic patient
Hypotension Vasopressor use
7/20 (35%) 4/20 (20%)
7/34 (20%) 6/34 (18%)
NS NS
between nonprophylactic and prophylactic patient
nsion Vasopressor use Cardiac morbidity
(45%) 7/20 (35%) 3/20 (15%)
(24%) 9/34 (27%) 0/34 (0%)
S NS .05
between patients with primary lesions and patients with
Hypotension Vasopressor use
14/54 (26%) 10/54 (19%)
1/21 (5%) 0/21 (0%)
.05 .05angenges
ypote
/20
/34
Nngesflation of either the Percusurge balloon or the angioplasty
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these five patients had both bradycardia and hypotension,
two had associated hypotension, and two had neither bra-
dycardia nor hypotension. One transient neurologic deficit
occurred when the protection device crossed the lesion.
This patient’s symptoms resolved by the end of the case.
There was no clinical evidence of perioperative stroke in
this patient series. There was no 30-day mortality.
Predictors of either bradycardia or hypotension were
analyzed by univariate analysis. Cardiac comorbidities in-
cluding hypertension, hypercholesterolemia, coronary ar-
tery disease, and a history of MI or coronary artery bypass
grafting were not associated with an increased incidence of
bradycardia or hypotension. Other comorbidities—includ-
ing diabetes mellitus, chronic renal insufficiency, and smok-
ing history—were also not predictive of hypotension or
bradycardia. The only demographic predictor of bradycar-
dia and hypotension that approximated statistical signifi-
cance in this cohort of patients was symptomatic carotid
disease (P  .054).
DISCUSSION
Our data suggest that prophylactic atropine may decrease
the incidence of bradycardia, hypotension, and cardiac mor-
bidity in patients with primary lesions undergoing CAS. Be-
cause most of our patients were asymptomatic, these findings
may be more valid in the subgroup of patients with primary
lesions. We observed a decreased incidence of intraoperative
bradycardia and of bradycardia in the perioperative period
when atropine was given prophylactically before balloon infla-
tion during CAS. We also observed a decreased incidence of
cardiac morbidity when prophylactic atropine was given in
these patients with primary lesions.
Patients with prior CEA in our series had a lower inci-
dence of intraoperative hypotension and need for vasopres-
sors. In the perioperative period, we observed a lower inci-
dence of bradycardia, hypotension, and vasopressor use, with
a trend toward a lower incidence of cardiac morbidity in
patients with prior CEA. Normally, carotid baroreceptor im-
pulses reach the medulla via the carotid sinus nerve and the
glossopharyngeal nerve. During CEA, there can be manipu-
lation and injury to the carotid sinus nerve that lies in the
carotid bifurcation. The injury and subsequent scarring may
interrupt a portion of the afferent nerve fibers, thus blunting
the baroreceptor reflex to stretch from the angioplasty balloon
or stent. Mehta et al11 found a higher incidence of hyperten-
sion after eversion CEA. They attributed the higher blood
Table VI. Comparison of perioperative hemodynamic cha
prior ipsilateral CEA
Variable Bradycardia Hypo
Primary 18/54 (33%) 17/54
Prior CEA 2/21 (10%) 1/21
P value (95% CI) .05 
CEA, Carotid endarterectomy; CI, confidence interval; NS, not significant.pressure in these patients to a loss of the baroreceptor reflexsecondary to nerve injury or transection during the procedure.
They also found a decreased need for procedural vasopressors
in the patients who had their carotid sinus nerve transected.
Bradycardia and hypotension after CAS have been previ-
ously reported with an incidence of 7% to 76%.2-8 Our overall
incidence of hypotension and/or bradycardia was 33%. The
incidence was 41% for primary lesions and 10% for recurrent
lesions. The highest incidence (55%) was in the subgroup of
patients with primary lesions who received selective atropine
(nonprophylactic group). We did not find any significant
demographic predictors for perioperative bradycardia and hy-
potension after CAS. It is interesting to note that although
most of our patients were asymptomatic, the only factor that
approached statistical significance in our series was a history of
symptomatic carotid disease (P  .054). Other authors have
found demographic factors associated with bradycardia and
hypotension after CAS. Mlekusch et al,2 in a review of 471
patients undergoing CAS, concluded that increased age and
coronary artery disease predicted perioperative hypotension
and bradycardia. Qureshi et al5 reviewed 51 CAS patients and
found increased age and previous MI to be predictive of
CAS-induced bradycardia and hypotension. In addition, in
contrast to what our data suggest, they concluded that symp-
tomatic carotid disease was protective against, and not predic-
tive of, postoperative hypotension.
Dangas et al4 observed that 44% of cases with hypotension
after CAS were preceded by intraprocedural hypotension.
Only 10.4% of their patients without post-CAS hypotension
had evidence of intraprocedural hypotension. Qureshi et al5
found intraprocedural hypotension to be the strongest predic-
tor of postprocedural hypotension. As in these prior studies,
we also found an association between intraprocedural hypo-
tension and postoperative hypotension. Our cohort of pa-
tients had a 13% (10/75) incidence of postoperative hypoten-
sion. Seven (70%) of the 10 patients with postoperative
hypotension also had intraoperative hypotension, whereas
only 3 (4%) of 68 patients without post-CAS hypotension had
intraprocedural hypotension (P .001).
Qureshi et al5 paradoxically found a higher risk of post-
procedural bradycardia associated with the prophylactic use of
atropine in patients undergoing CAS.We did not have similar
results. Although this was not statistically significant, we
found a lower incidence of bradycardia in the postoperative
period for the prophylactic group (15%) compared with the
nonprophylactic group (30%).
It should be recognized that a well-known side effect of
atropine is tachycardia. With resultant tachycardia, there is an
between patients with primary lesions and patients with
n Vasopressor use Cardiac morbidity
) 16/54 (30%) 3/54 (6%)
) 1/21 (5%) 0/21 (0%)
.05 NSnges
tensio
(32%
(5%
.05increased cardiac oxygen demand that may result in an in-
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incidence of operative tachycardia in patients given 0.5 to 1
mg of atropine prophylactically before balloon inflation dur-
ing CAS, and we found no increase in the incidence of cardiac
complications in these patients. We do, however, recognize
that with a relatively small sample size, the possibility of a type
II error exists.
In conclusion, prophylactic atropine administration be-
fore balloon inflation in primary CAS patients reduced the
incidence of bradycardia and cardiac morbidity in our series.
CAS after prior ipsilateralCEAwas associatedwith a decreased
incidence of perioperative bradycardia, hypotension, and va-
sopressor requirement, with a trend toward a lower incidence
of cardiacmorbidity.On the basis of our data, we recommend
consideration of routine prophylactic atropine administration
in patients with primary lesions undergoing CAS. Further
studies should be performed to confirm these findings.
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Atropine as routine prophylaxis against bradycardia has been
incorporated in many carotid artery stenting (CAS) protocols as
evident from several published carotid stent trials. This is remark-
able considering the waning popularity of atropine as an adjunct to
general anaesthesia, particularly for the cardiovascularly compro-
mised patient. Evidence for the use of atropine in CAS either on
indication or prophylactically is currently lacking.
Cayne et al have addressed this question in a retrospective study.
Although patients with CAS after prior carotid endarterectomy were
also included in the current analysis, the main conclusion pertains to
primary CAS procedures. In the initial 20 CAS procedures, the
authors noted episodes of bradycardia in 10 patients and they decided
to start atropine prophylactically in the subsequent patients.With only
three intraoperative episodes of bradycardia in the following 34 pro-
cedures, a statistically significant difference with the historic controls
was found. In their conclusion, the authors recommend that prophy-
lactic atropine use be considered in patients undergoing primaryCAS.
There are several reasons why care should be taken before chang-
ing clinical practice on the basis of this small study. Atropine admin-
istration and the resulting tachycardia may increase the risk of cardiac
complications. This is exactly why atropine has lost its appeal with
anesthesiologists dealing with vascular surgery patients. In fact, cur-
rent guidelines recommend the perioperative use of medication with
opposite effects (-blockers).1
The routine use of atropine appeared to have had no impact on
periprocedural cardiac morbidity, but as 50% of the patients in the
prophylactic group and 70% in the non-prophylactic group had a
history of coronary artery disease, this can also be interpreted as
another argument against the validity of the historic control group.
Obviously, this study carries all the drawbacks of a retrospectiveD, Nijmegen, The Netherlands
is in effect. Although none of the individual baseline characteristics
show a statistically significant difference in the univariate analysis of
the two groups, most of the risk factors are skewed towards the
nonprophylactic group. This implies that the historic control group
consisted of sicker patients, which may have contributed to higher
complication rates.
Furthermore, the definitions of bradycardia and hypotension
are subjective. Although bradycardia appeared to bemore frequent
in the nonprophylactic group, there is no evidence for this having
resulted in worse outcomes.
Finally, this being a historic control study, the reduction of
bradycardiamay also be related to changes in techniques andmaterials
over time. With smaller size postdilatation balloons, or entirely aban-
doning postdilation, the risks of bradycardia may have diminished
irrespective of the use of prophylactic atropine.
Cayne et al have provided persuasive arguments for reconsid-
ering prophylactic atropinemedication in CAS procedures, but it is
level 4 evidence at best. In view of the potential risks of tachycardia
in these particular patients and the well-established benefit of
-blockade, only a randomized trial will solve this issue.
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